A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

Woodcock, V.K., Clive, S., Wilson, R.H. et al. (11 more authors) (2018) A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 118 (6). pp. 770-776. ISSN 0007-0920

Abstract

Metadata

Authors/Creators:
  • Woodcock, V.K.
  • Clive, S.
  • Wilson, R.H.
  • Coyle, V.M.
  • Stratford, M.R.L.
  • Folkes, L.K.
  • Eastell, R. ORCID logo https://orcid.org/0000-0002-0323-3366
  • Barton, C.
  • Jones, P.
  • Kazmi-Stokes, S.
  • Turner, H.
  • Halford, S.
  • Harris, A.L.
  • Middleton, M.R.
Copyright, Publisher and Additional Information: This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: Targeted therapies
Dates:
  • Accepted: 12 December 2017
  • Published (online): 13 February 2018
  • Published: 20 March 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 26 Feb 2018 12:57
Last Modified: 07 Oct 2020 09:44
Status: Published
Publisher: Cancer Research UK
Refereed: Yes
Identification Number: https://doi.org/10.1038/bjc.2017.484
Related URLs:

Download

Share / Export

Statistics